NTRK2 and diabetic retinopathy: To prevent trkB downregulation, alternate therapies with doublets and triplets in in vivo animal models may be one of the options for long-lasting topical administration of axoprotectants for the treatment of chronic retinal diseases such as diabetic retinopathy.